Intestinal ultrasound is a painless, non-invasive scan that can measure how inflamed your child's bowel is shortly after their Crohn's disease diagnosis — and this study found that those early measurements are strong predictors of how well your child will respond to treatment over the next year. Importantly, the bowel began showing improvement as early as one month after starting treatment, and children whose bowel wall thickness dropped to a healthy level by 6 months were much more likely to be in full remission by the end of the year without needing more intensive therapy.

This study examined whether routine pelvic MRI at the time of diagnosis in pediatric Crohn's disease patients could detect subclinical perianal disease that physical examination alone would miss, finding that roughly 1 in 5 newly diagnosed patients had perianal disease detectable only by MRI. These MRI-positive but asymptomatic patients were significantly more likely to require biologic therapy and perianal surgery earlier than MRI-negative patients, despite showing no outward symptoms at diagnosis. The authors conclude that integrating routine pelvic MRI into the diagnostic workup for pediatric Crohn's disease could meaningfully inform earlier treatment decisions and potentially improve long-term outcomes.

This study used machine learning to analyze clinical and lab data from 308 children with Crohn's disease to predict which patients would respond well to exclusive enteral nutrition (EEN) — a liquid-only diet used as a first-line treatment — finding that the models could predict both short-term remission and longer-term steroid-free remission better than chance. While the models were moderately accurate rather than perfect, the findings support the idea that everyday clinical information could one day be used to build practical tools that help doctors personalize treatment decisions for children with Crohn's disease from the very start.

This study established a national biobank collecting surgical tissue from children with Crohn's disease across 10 Canadian children's hospitals, demonstrating that coordinating multicenter tissue collection and overnight shipping to a central lab is feasible, with 18 patients enrolled across 7 sites since 2023. Early results are promising — high-quality imaging and RNA sequencing successfully identified 560 genes that distinguish inflamed from non-inflamed bowel — suggesting this biobank can generate the kind of high-quality translational data needed to better understand why Crohn's disease develops and progresses in pediatric patients.

This study directly compared intestinal ultrasound (IUS) and MRI enterography (MRE) in 58 newly diagnosed pediatric Crohn's disease patients, finding that both performed similarly in detecting inflammation in the distal small bowel and colon, but MRE tended to over-report disease in the more proximal small bowel and over-detected strictures in the terminal ileum compared to what endoscopy confirmed. Given that IUS is cheaper, more accessible, and radiation-free while performing comparably to MRE for the most common disease locations, the authors conclude that IUS is a viable alternative to repeated MRE for both initial assessment and ongoing monitoring in pediatric Crohn's disease.

This study examined whether measuring the submucosal layer thickness (SMT) on intestinal ultrasound could help identify bowel inflammation in pediatric Crohn's disease and ulcerative colitis patients, finding that the submucosal layer was significantly thicker in inflamed versus normal bowel and correlated moderately well with endoscopic disease severity in both conditions. Key pediatric-specific cutoffs were identified — a submucosal thickness of ≥1.3 mm for Crohn's disease and ≥1.1 mm for ulcerative colitis — with the SMT-to-total bowel wall thickness ratio also proving useful for detecting UC inflammation specifically, suggesting that submucosal measurement adds meaningful diagnostic information beyond total bowel wall thickness alone in pediatric IBD assessment.